Brian Feagan


Scientist Emeritus

Why I Became a Scientist

I became a scientist because it was clear during my training as a physician that many treatment decisions are made on the basis of poor or little evidence and that a great need exists to apply the principles of epidemiology to clinical care.  I was fortunate to start my career at a time when the "evidence-based" medicine movement was gaining momentum, and have greatly enjoyed designing and implementing large scale clinical trials that answer questions that have direct implications for patient care. 

Research Summary

Our group is currently conducting more than 30 randomized controlled trials evaluating new treatments for Crohn's disease, ulcerative colitis and Type I diabetes mellitus.


  • MD - Faculty of Medicine, University of Western Ontario, London, Ontario, Canada (1983)
  • MSc (Medical Microbiology) - University of London, School of Hygiene and Tropical Medicine, London, England (1979)
  • BSc (Bacteriology & Immunology) - Faculty of Science, University of Western Ontario (1977)


  • Epidemiology and Biostatistics: Postgraduate Training, University of Western Ontario
  • Gastroenterology: Clinical Fellow, University of Western Ontario
  • Medicine: Residency in Internal Medicine, University of Western Ontario


  • Best Abstract, Falk Symposium
  • Bristol Prize, International Medicine, University of Western Ontario
  • CV Mosby Scholarship, Medical Microbiology, University of Western Ontario
  • Merck, Sharpe, Dohme, Therapeutics Award, University of Western Ontario
  • Medical Research Council Summer Studentship
  • Gold Medalist, Microbiology and Immunology, University of Western Ontario


  1. Travis S, Feagan BG, Rutgeerts P, van Deventer S.  The Future of Inflammatory Bowel Disease Management: Combining Progress in Trial Design with Advances in Targeted Therapy.  J Crohns Colitis 2012 Feb; 6 Suppl2: S250-9

  2. Feagan BG, Greenberg GR, Wild G, et al. Treatment of Active Crohn's Disease with MLN0002: A Humanized Antibody to the Alpha4Beta7 Integrin. Clinical Gastroenterology & Hepatology 2008; 6(12): 1370-7

  3. Sandborn WJ, Feagan BG, Lichtenstein GR.  Medical Management of Mild to Moderate Crohn's Disease Evidence-Based Treatment Algorithms for Induction and Maintenance of Remission.  Ali Pharma & Thera 2007; 26(7): 987-1003

  4. Feagan BG, Reinisch W, Rutgeerts P, et al.  The Effects of Infliximab Therapy on Health-related Quality of Life in Ulcerative Colitis Patients.  Am J Gastroenterol 2007 Aprl 102(4): 794-802

  5. Sandborn WJ, Feagan BG, Stoinov S, et al.  Certolizumab Pegol for the Treatment of Crohn's Disease.  New Engl J Med 2007: 357(3): 228-238

  6. Rutgeerts P, Sandborn WJ, Feagan BG, et al.  Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis.  New Engl J Med 2005: 353(23): 2462-2476

  7. Feagan BG, Greenberg GR, Wild G, et al.  Treatment of Ulcerative Colitis with a Humanized Antibody to the Alpha4Beta7 Integrin.  New Engl J Med 2005: 352(24): 2499-2507

  8. Hanauer SB, Feagan BG, Lichtenstein GR et al.  Maintenance Infliximab for Crohn's Disease: The ACCENT 1 Randomized Trial.  Lancet 2002 (May 4): 359(9317): 1541-49

  9. Feagan BG, Fedorak RN, Irvine EJ, et al.  A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease.  N Engl J Med 2000: 242(22): 11627-1632

  10. Feagan BG, Rochon J, Irvine EJ, et al.  Methotrexate for the Treatment of Crohn's Disease.  New Engl J Med 1995; 332(5): 292-297

Contact Info

Lesley McLellan & Heather Carter
Executive Assistants: and
Phone: 519-931-5289 or 519-858-5087